Respiratory Tract Disease Research Articles

How to perform a transtracheal aspirate in horses for diagnosis of lower respiratory tract disease.

To describe indications for and demonstrate the technique to perform a transtracheal aspirate in horses. Transtracheal aspirate is indicated to collect samples for cytology and bacteriologic culture in cases of suspected pneumonia or other lower respiratory tract disease. 1 healthy university-owned horse was used for demonstration purposes. Images of clinical case samples from the University of Illinois Veterinary Teaching Hospital are shown. The horse is restrained and sedated with detomidine or xylazine to facilitate restraint and butorphanol to minimize coughing. The ventral neck is clipped and aseptically prepared. The site of planned puncture proximal to the bifurcation of the sternocephalicus is anesthetized with lidocaine. Two to three 30-mL syringes are filled with saline aseptically. A stab incision is made with a No. 15 blade to the depth of the trachea. The trocar is advanced between tracheal rings on midline, the stylet removed, and the aspiration catheter advanced through the trocar to the level of the proximal horizontal trachea. Sterile saline (30 mL) is infused rapidly, and suction is applied to the syringe while slowly withdrawing the catheter until fluid is retrieved. The catheter and trocar are withdrawn and the puncture site covered with antimicrobial ointment or a light bandage. Samples are collected in a plain tube for bacteriologic culture and EDTA for cytology. The visual appearance of purulent effluent confirms severe pneumonia. Transtracheal aspirate is minimally invasive and simple to perform with available kits. Samples provide valuable information to guide treatment decisions and selection of antimicrobials for horses with suspected lower respiratory tract disease.

Development of a reporter feline herpesvirus-1 for antiviral screening assays

Feline herpesvirus type 1 (FHV-1), a member of the Herpesviridae family, is one of the most important pathogens that causes upper respiratory tract disease in felines. Following infection, FHV-1 can spread retrogradely to the trigeminal ganglia, establishing a life-long latency. Although vaccines are available for routine feline vaccination, FHV-1 is still an agent that poses a serious threat to feline health. There are currently no specific drugs for the treatment of FHV-1. To facilitate the screening of antiviral drugs, we constructed a reporter FHV-1 virus, which expresses a secreted Gaussia luciferase (GLuc) and a bright green fluorescent protein, mNeonGreen. The reporter virus shows slower growth than does the wild-type FHV-1. The expression of the two reporter genes, Gluc and mNeonGreen, was consistent with viral propagation and remained stable during continuous passage in CRFK cells, even after twenty rounds. In addition, the known inhibitor ganciclovir was used to confirm the characteristics of the reporter virus for drug screening. We found that the reporter FHV-1 is suitable for antiviral screening assays. Overall, our work provides a useful tool for screening drugs to combat FHV-1.

Is a Consensus Case Definition for Viral Associated Lower Respiratory Tract Disease (LRTD) in Clinical Trials Possible?

Lower respiratory tract illness or disease (LRTI/LRTD) represents a significant source of morbidity and mortality following viral respiratory illnesses, yet a consensus definition for this outcome is lacking. Recent studies of novel vaccines against respiratory syncytial virus (RSV) for older adults used LRTI/LRTD as the primary outcome to assess vaccine efficacy. However, the different vaccine trials have used highly variable criteria to define this outcome, leading to difficulty in comparison of vaccine efficacy results between trials. Here we review the key differences in criteria for case definitions, highlight strategies to best approximate compatibility between definitions, and review vaccine efficacy results among currently US Food and Drug Administration (FDA)-approved vaccines using these strategies. We hope this overview will support the need to develop a consensus definition for LRTI/LRTD to improve future research related to viral respiratory disease.

Dekanilacija pri otrocih: predstavitev protokola in naših izkušenj

Background: Tracheostomy increases the morbidity of children, so it is desirable to remove the tracheal cannula (TC) or perform the decannulation as soon as possible. The clinical assessment ensures the child meets the conditions for decannulation. This is followed by decannulation, performed in a hospital environment according to the paediatric decannulation protocol, which guarantees success and safety. The purpose of the study was to analyse the factors influencing decannulation in tracheotomised children and to present the decannulation protocol used at the Department for Otorhinolaryngology and Cervicofacial Surgery of the University Clinical Centre Ljubljana. Methods: Data on tracheotomies and decannulations (age at tracheotomy, indication for tracheotomy, associated diseases, complications of tracheotomy, date of decannulation, and surgical closure of tracheostomy) were retrospectively collected from 43 tracheotomised children. Results: 53.5% (23/43) of children were successfully decannulated (median age = 729.5 days) at a median time of 259.0 days from the tracheotomy. Dysphagia with aspiration was statistically significantly more common among non-decannulated children (p = 0.016) than decannulated children. In the group of decannulated children, the time to decannulation was longer in those under one year of age at the time of tracheotomy (p < 0.001), in those with comorbidities of the lower respiratory tract (p = 0.001 ) or prematurity (p = 0.005). The factor that statistically significantly increased time to decannulation was age at tracheotomy of one year or less (p < 0.001). Conclusion: The paediatric decannulation protocol ensures the successful and safe removal of TC. Dysphagia with aspiration is a common reason for preventing decannulation in children. Risk factors for an increased time to decannulation are age less than one year at tracheotomy, associated lower respiratory tract disease, and prematurity.

IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease

IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease

Topical antibiotics for the treatment of upper respiratory tract diseases

Actuality. Antibiotic resistance includes the unjustified use of topical antibacterial agents.Objective. To study the frequency of topical and systemic antibacterial drugs among adults with symptoms of otorhinolaryngological diseases over the past 6 months and the role of physicians in prescribing antibacterial drugs.Methods: online questioning of adults. The data from a survey of 111 respondents aged over 18 years were analyzed. A group (61 out of 111) of respondents (54.96%) experiencing symptoms of otorhinolaryngological diseases and using medications 6 months before the survey was conducted was identified.Results: 31.15% of respondents took systemic antibiotics. Of all respondents who received a systemic antibacterial drug, only 14 out of 19 (73.68%) took it as prescribed by a physician and 1 (2.38%) was prescribed by a pharmacist. At the same time, the respondents used all topical antibacterial drugs — 4 cases (6.6%) without the recommendation of a physician or pharmacist.Conclusion. The prevalence of topical antibacterial drugs for the treatment of upper respiratory tract diseases among the study population was low, but the frequency of their use without the appointment of a specialist was high.

Epidemiological dynamics at the peak of the COVID-19 pandemic among children in Rio Grande do Sul, Brazil

Objective: to describe the profile of children infected by SARS-CoV-2 in Rio Grande do Sul, Brazil, between March 1, 2020, and April 30, 2021, comparing infection rates and disease evolution stratified by age group. Methods: this cross-sectional study used data from COVID-19-confirmed cases from a public state database in children aged zero–nine. Results: the study sample comprised 35,131 children. We found the highest infection rate in the age group of zero–four years old, 3.8% (95%CI:3.3%-4.3%). Of the patients, 3.8% (n = 1,323) had comorbidities, the most prevalent being respiratory tract disease (56.2%, n=829). 450 (1.3%) children developed Severe Acute Respiratory Syndrome (SARS), with a lethality rate of 0.05% (95%CI:0.02%-0.08%). However, we found that both outcomes decreased when age increased; thus, a PR of 8.68 (CI95%:6.86-10.99) was estimated for SARS and PR=5,52 (CI95%:1,26- 24,09) for death in the presence of respiratory comorbidity. Discussion: this study revealed a low mortality rate in this population. The presence of respiratory comorbidities increases the risk of SARS and death. Both outcomes increased in younger age groups.

Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care.

Objective: To describe the implementation of nirsevimab for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in a pediatric hospital, focusing on strategies to ensure equitable access and address logistical challenges. Additionally, we aimed to identify predictors of nirsevimab deferral among eligible infants. Patients and Methods: Our hospital implemented a universal immunization campaign to all eligible infants, including those discharged from the newborn nursery, intermediate care nursery (ICN), and neonatal intensive care unit (NICU). We identified key drivers and barriers, formed a multidisciplinary team, and applied a systematic approach for integration of nirsevimab orders into existing workflows. We developed and disseminated educational resources for staff and caregivers. After the implementation, we conducted univariate and multivariate analyses to identify predictors of nirsevimab deferral to evaluate implementation success and possible gaps. Results: Despite challenges, we offered nirsevimab to 99% of eligible infants prior to discharge from the newborn nursery, ICN, and NICU with 71% receiving the immunization. On multivariate analysis, independent predictors of nirsevimab deferral included preferred language of English, deferral of hepatitis B vaccine, discharge from the newborn nursery, and public insurance. Conclusions: Our implementation strategy ensured equitable access to nirsevimab for newborns, with both our high uptake and acceptance rate underscoring the effectiveness of our approach. Key strategies for success included early stakeholder engagement, multidisciplinary collaboration, and proactive logistical planning. Our approach serves as a model for other institutions to offer nirsevimab prior to hospital discharge and highlights the importance of addressing both clinical and socioeconomic barriers.

Impact of Viral Lower Respiratory Tract Infection (LRTI) in Early Childhood (0-2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health (NIH) Workshop Summary.

Viral lower respiratory tract infections (LRTI) are ubiquitous in early life. They are disproportionately severe in infants and toddlers (0-2 years), leading to more than 100,000 hospitalizations in the United States per year. The recent relative resilience to severe Coronavirus disease (COVID-19) observed in young children is surprising. These observations, taken together, underscore current knowledge gaps in the pathogenesis of viral lower respiratory tract diseases in young children and respiratory developmental immunology. Further, early-life respiratory viral infections could have a lasting impact on lung development with potential life-long pulmonary sequelae. Modern molecular methods, including high-resolution spatial and single-cell technologies, in concert with longitudinal observational studies beginning in the prenatal period and continuing into early childhood, promise to elucidate developmental pulmonary and immunophenotypes following early-life viral infections and their impact on trajectories of future respiratory health. In November 2019, under the auspices of a multi-disciplinary Workshop convened by the National Heart Lung Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, experts came together to highlight the challenges of respiratory viral infections, particularly in early childhood, and emphasize the knowledge gaps in immune, virological, developmental, and clinical factors that contribute to disease severity and long-term pulmonary morbidity from viral LRTI in children. We hope that the scientific community will view these challenges in clinical care on pulmonary health trajectories and disease burden not as a window of susceptibility but as a window of opportunity.

Current Review of Comorbidities in Chronic Rhinosinusitis.

Chronic rhinosinusitis (CRS) is a heterogenous disease with a significant impact on patient quality of life and a substantial economic burden. CRS is associated with several systemic inflammatory conditions. We provide an updated review of CRS comorbidities as a springboard for future comorbidity mapping and potential therapeutics. The link between environmental allergies and CRS is most evident for central compartment atopic disease (CCAD) and allergic fungal rhinosinusitis (AFRS) subtypes but remains inconclusive for CRS overall. The association between asthma and CRS, reinforced by the unified airway theory, is evidenced by their response to similar biologic therapies. Another lower respiratory tract disease, COPD, has up to a 50% co-occurrence with CRS and warrants careful screening and treatment. Eosinophilic esophagitis and CRS share eosinophilic inflammation in different sites, meriting further research. Obesity not only presents physiological challenges but also correlates with a more severe subset of CRS. Diabetes mellitus is associated with CRSwNP, possibly secondary to therapeutics with steroids. Autoimmunity may contribute to nasal polyp formation through cytokines such as B-cell activating factor (BAFF), offering potential for future therapeutics. This review illustrates the need to employ a macroscopic approach in clinical decision making and treatment of CRS. Comorbidities may contribute to an overall proinflammatory state, magnify severity of symptoms, be a source of treatment resistance, and even an opportunity for future therapeutics.

Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults.

As no standard case definitions for respiratory syncytial virus-associated lower respiratory tract disease (RSV-LRTD) in adults are available, this study analyzed definitions for severe RSV-LRTD from previously published data in hospital and community cohorts of adults with RSV-associated symptoms. The frequency, sensitivity, and specificity of acute respiratory disease symptoms among hospitalized and community cohorts of adults with RSV were analyzed. RSV-LRTD signs/symptoms assessed included shortness of breath (dyspnea), cough and/or fever, wheezing/rales/rhonchi (abnormal lung sounds by auscultation), sputum production, tachypnea, hypoxemia, and pleuritic chest pain. Dyspnea and tachypnea provided the best differentiation between hospitalized and community RSV-positive cases. The severe RSV-LRTD case definition yielding one of the highest and best-balanced sensitivity and specificity was dyspnea paired with either abnormal lung sounds by auscultation, hypoxemia, tachypnea, cough and/or fever, sputum, or chest pain. Dyspnea alone, and in combination with certain other lower respiratory tract disease signs/symptoms, was a leading symptomatic indicator for severe RSV outcomes. These results contribute to the harmonization of case definitions for RSV disease.

RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy.

In May 2023, The United States Food and Drug Administration (FDA) approved a Pfizer©-sponsored (COMPANY, CITY, STATE, COUNTRY) bivalent RSVpreF (respiratory syncytial virus prefusion F protein-based vaccine) RSV vaccine (AbrysvoTM [COMPANY, CITY, STATE, COUNTRY]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, FDA trials sponsored by GSK© (COMPANY, CITY, STATE, COUNTRY) on a similar RSVpreF RSV vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use nearly identical pre-fusion F-protein technology, we sought to synthesize and evaluate the existing high-quality literature on their effectiveness and safety. From inception until March 15, 2024, we searched for randomized controlled trials (RCTs) on this topic. We used Review Manager (RevMan 5.4.1) (COMPANY, CITY, STATE, COUNTRY) to perform the analysis with 95% confidence intervals and risk ratios (RR). Our search yielded three large RCTs. From a safety perspective, many maternal side effects were greater in the RSVpreF group, with an increased incidence of local reactions (RR, 5.98 [3.68, 6.83]; P=0.01; I2=0%), blood disorders (RR, 1.07 [0.69, 1.66]; P=0.78; I2=0%), fatigue (RR, 1.05 [1.00, 1.10]; P=0.07; I2=0%), joint pain (RR, 1.60, 1.39 [0.68, 2.86]; P=0.37; I2=59%), cardiac disorders (RR, 1.19 [0.80, 1.77]; P=0.38; I2=0%), headache (RR, 0.80 [0.30, 2.10]; P=0.65; I2=0%), fever (RR, 0.90 [0.20, 4.16]; P=0.89; I2=57%), gastrointestinal disorders (RR, 1.04 [0.70, 1.56]; P=0.83; I2=0%), and pregnancy complications (RR, 1.01 [0.65, 1.56]; P=0.97; I2=17%). The vaccinated group demonstrated significant reduction RSV-lower respiratory tract disease (LRTD) cases (RR, 0.44 [0.33, 0.57]; P=0.01), severe LRT illness (RR, 0.29 [0.19, 0.44]; P=0.01), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.03); however, no significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appeared to have acceptable short-term safety for newborns, but did not produce a significant decrease in neonatal death.

Hardware treatment of diseases of the upper respiratory tract in acute respiratory viral infections

Acute respiratory viral infections are among the most common diseases affecting the health of the population and often leading to complications from the upper respiratory tract. Medical treatment of acute respiratory viral infection is often complemented by hardware therapies that help reduce the risk of complications and accelerate recovery. This paper describes modern hardware methods for the treatment of acute respiratory viral infections, including low-frequency ultrasound cavitation, photochromotherapy, ultraviolet irradiation and UHF therapy. The clinical efficacy was evaluated in comparison with drug-based approaches. The possibilities of using these methods both in medical institutions and at home using the MULTILOR device were also investigated. Data analysis has shown that the use of hardware treatment methods significantly reduces the severity of symptoms of acute respiratory viral infections, shortens the duration of the disease and reduces the risk of complications. It is important to note that devices such as MULTILOR allow for treatment at home, increasing the availability of therapy. Hardware treatment of acute respiratory viral infections (ARVI) of the upper respiratory tract is a promising direction in modern medical practice, due to its proven effectiveness, safety and variety of technologies used. The inclusion in therapeutic regimens of such methods as low-frequency ultrasonic cavitation, ultraviolet irradiation (UVF), as well as UHF therapy, allows not only to significantly accelerate the regression of clinical symptoms, but also prevents the development of complications often associated with acute respiratory viral infections. The combined effect of these methods contributes to a significant reduction in symptoms, improvement of the condition of the mucous membranes and prevention of disease recurrence.

Acute purulent otitis media: key features of pathogenetic therapy

Acute purulent otitis media is an inflammation of the mucous membrane of the middle ear, a disease often encountered both in pediatric practice and in adult patients. The prerequisite for the development of this pathology is a violation of the function of the auditory tube, often occurring in inflammatory diseases of the upper respiratory tract, as well as in conditions of hypertrophy of the pharyngeal tonsil. Bacterial microflora, represented in most clinical cases by S. pneumoniae and H. influenzae, traditionally acts as an etiological factor of acute purulent otitis media. The authors of the article discuss the features of the clinical course of the disease, the causes of frequent recurrent course and the risk of developing purulent complications. The article highlights current problems of diagnosis and treatment of acute otitis media at different stages, including rational and justified use of antibacterial drugs. The authors consider the possibility of using topical anti-inflammatory and analgesic drugs as an alternative to the systemic use of non-steroidal anti-inflammatory drugs (NSAIDs) for rapid relief of the main symptoms of the disease. The authors conclude that ear drops containing lidocaine and phenazone, due to their combined action, are effective as a symptomatic treatment for acute otitis media, including its recurrent course, help reduce the frequency of prescribing antibacterial drugs, effectively relieve pain, reduce the duration of the disease and significantly improve the patient’s quality of life. Due to the high safety profile and the possibility of using ear drops with phenazone and lidocaine from birth, this dosage form finds its successful application in pediatric practice.

Pharmacokinetics of Salbutamol in Thoroughbred Horses After a Single Intravenous or Inhaled Administration.

Salbutamol is a short-acting and selective beta-2 adrenergic agonist. Inhaled (IH) administration of salbutamol is widely used to control lower respiratory tract disease in horses. Here, we estimated the pharmacokinetic parameters of salbutamol after a single intravenous (IV) or IH administration in six horses, and we statistically analysed the detection times with various dosing regimens. Plasma and urine concentrations of salbutamol were measured by liquid chromatography-tandem mass spectrometry, and data were modelled by using a nonlinear mixed effect model followed by Monte Carlo simulation (MCS). With IH salbutamol, the maximum plasma concentration was 0.12 ± 0.06 ng/mL at 0.29 ± 0.17 h after administration. Typical values were, for clearance, 1.53 L/kg/h; distribution volume at steady state, 5.43 L/kg; terminal half-life, 6.06 h; IH bioavailability, 19.0%; and urine to plasma ratio, 2057. Statistically estimated 95th percentile detection times in the urine at levels below the international screening limit (0.5 ng/mL) proposed by the International Federation of Horseracing Authorities, as simulated in 5000 horses by MCS, were 44 h after 1.6 μg/kg q 24 and 54 h after 1.6 μg/kg q 4 h over a 3-day IH administration period.

The use of azithromycin in the treatment of inflammatory diseases of the upper respiratory tract and ear

Despite the extensive accumulated clinical experience, inflammatory diseases of the upper respiratory tract and ear still remain an important problem in the field of otorhinolaryngology, especially pediatric practice, since these diseases are associated with the risk of complications. One of the reasons for the ineffectiveness of conservative treatment is the incorrect initial antibacterial therapy. Errors in antimicrobial therapy are associated with both insufficient knowledge of clinical pharmacology by doctors and incorrect interpretation of anamnestic and clinical data, which leads to incorrect treatment of CCA. The aim of the work is to analyze the use of azithromycin in the treatment of upper respiratory tract and ear infections in children, based on pharmacological characteristics, as well as to consider current methods of antibiotic therapy in pediatric practice. An analysis of the literature and our own observations allows us to conclude that azithromycin is an effective antibacterial drug. Taking into account the low toxicity and good bioavailability, azithromycin continues to be one of the main drugs in the arsenal of doctors for the treatment of various infections, including respiratory diseases and infectious processes of ENT organs in children caused by both typical and atypical bacterial pathogens. The convenient dosage form and simple dosage regimen make this drug a popular choice in outpatient pediatric practice, which confirms the widespread use and trust in this antibacterial drug among both doctors and parents.

Bovine respiratory disease: prevention and control

Bovine respiratory disease (BRD) presents a diagnostic challenge as clinical signs alone may not identify the underlying cause. Whilst clinical signs may suggest pneumonia, it is important to recognise that BRD encompasses upper and lower respiratory tract disease. Both bacterial and viral pathogens are implicated in BRD, and co-infections are common, further complicating diagnosis.

Comparative phytochemical profile and biological activity of three Terminalia species as alternative antimicrobial therapies

Ethnopharmacological relevanceMedicinal plants can help combat antibiotic resistance by providing novel, active molecules. Three plant species of the Terminalia genus are widely used in traditional medicine in the Mouhoun region for the treatment of cutaneous and respiratory diseases. Therefore, it is important to determine the ethnopharmacological potential of bark extracts from the trunks of these three Terminalia species. Aim of the studyThis study compared the phytochemical and biological activities of extracts from three Terminalia species to determine their ethnopharmacology. Materials and methodsThe medicinal properties of the extracts were assessed based on their ability to inhibit the growth of the following microorganisms: Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Candida albicans, Candida krusei, Candida glabrata, and Candida tropicalis. The significant interest in these medicinal plants among the local communities were elucidated by their antioxidant properties and phytochemical composition, along with the detection key bioactive compounds. Major phytochemical groups and phenolic compounds were determined using high-performance liquid chromatography with a diode array detector. These phytochemical findings were validated by evaluating the antioxidant capacity of the extracts using DPPH, FRAP, and ABTS assays. ResultsHydroethanolic, ethanolic, and hexane extracts from the bark of three Terminalia species inhibited the growth of both bacteria and fungi, as evidenced by their minimum inhibitory concentrations (MICs).The findings showed that Terminalia species were most effective against various tested bacteria and fungi, with MICs ranging from 0.1 to 6.25 mg/mL. Terminalia avicennioides, Terminalia macroptera, and Terminalia laxiflora extracts demonstrated 50 % inhibition of DPPH at concentrations ranging from 0.04 to 0.6 mg/mL. Phytochemical analysis revealed the presence of several families of chemical compounds, such as total phenolics and flavonoids. Phenolic compounds identified by HPLC in ethanolic extracts of T. avicennioides, such as isorhamnetin, quercetin, and ferulic acid, are recognised for their antimicrobial and antioxidant properties. ConclusionThese findings establish an ethnobotany for these three Terminalia species, with their chromatographic characteristics facilitating the identification of key molecules of interest. The ethanolic extract of T. avicennioides can be used in phytomedicinal formulations against bacterial (P. aeruginosa and S. aureus) and fungal (C. albicans and C. glabrata) infections, both of which are recurrently recorded in certain skin and respiratory tract diseases.

Immunological and Molecular Method for the Diagnosis of Human Bocavirus in Patients with Respiratory Infections in Mosul, Iraq

Immunological and Molecular Method for the Diagnosis of Human Bocavirus in Patients with Respiratory Infections in Mosul, Iraq

Prospective Attitudes Towards Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women in Greece

Respiratory Syncytial Virus (RSV) is a common respiratory pathogen with high morbidity and mortality, especially in children under two years of age. Severe RSV infection poses a significant threat to healthcare systems, making vaccination an utmost need. In August 2023, the U.S. FDA approved an RSV maternal vaccine to prevent lower respiratory tract disease (LRTD) in infants throughout their first six months of life. This cross-sectional survey was designed to evaluate pregnant women’s willingness to receive the vaccine during pregnancy. An anonymous survey was administered from April 2023 to December 2023 to pregnant women aged above 16 years old attending gynecology wards of randomly selected public and private hospitals in Crete. The primary outcome was the intention to receive the vaccine. Univariable and multivariable analyses were carried out to identify factors associated with the intention to get vaccinated. Questionnaires were distributed to a sample of 335 pregnant females who agreed to participate in this study. The intention to get vaccinated against RSV was positively associated with educational level, the presence of school-age children, RSV infection awareness, intention to get routine pregnancy vaccines according to the National Immunization Program (NIP), and previous vaccination against COVID-19. The majority of pregnant females were not familiar with the term RSV and the upcoming vaccine. An educational campaign regarding RSV infection and its vaccine is required to improve women’s perceptions and to support healthcare workers in promoting it upon its availability in Greece.